CO6650363A2 - Preparación recubierta con partículas finas - Google Patents

Preparación recubierta con partículas finas

Info

Publication number
CO6650363A2
CO6650363A2 CO13003384A CO13003384A CO6650363A2 CO 6650363 A2 CO6650363 A2 CO 6650363A2 CO 13003384 A CO13003384 A CO 13003384A CO 13003384 A CO13003384 A CO 13003384A CO 6650363 A2 CO6650363 A2 CO 6650363A2
Authority
CO
Colombia
Prior art keywords
oral cavity
rapid disintegration
coated
isobutyloxyphenyl
cyano
Prior art date
Application number
CO13003384A
Other languages
English (en)
Inventor
Kazuhiro Nakamura
Teppei Ogawa
Tomoya Akutagawa
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6650363(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CO6650363A2 publication Critical patent/CO6650363A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una preparación que no se siente sustancialmente el estímulo en la cavidad oral y en la faringe y que al mismo tiempo se mantiene excelentes propiedades de elución y desintegración rápida en la cavidad oral aún mediante la conservación en condiciones de alta temperatura y alta humedad, siendo una tableta de desintegración rápida en la cavidad oral con ácido 2- (3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico como ingrediente activo.Tableta de desintegración rápida en la cavidad oral que contiene las partículas que son las partículas nucleares que contienen ácido 2-(3-ciano- 4isobutiloxifenil)-4-metil-5-tiazolcarboxíliCo, recubiertas con la capa que contiene cpo1ímero de ácido metacrílico y sobrecubiertas con la capa que contiene azucares solubles en agua.
CO13003384A 2010-07-09 2013-01-09 Preparación recubierta con partículas finas CO6650363A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010156874 2010-07-09

Publications (1)

Publication Number Publication Date
CO6650363A2 true CO6650363A2 (es) 2013-04-15

Family

ID=45441336

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13003384A CO6650363A2 (es) 2010-07-09 2013-01-09 Preparación recubierta con partículas finas

Country Status (23)

Country Link
US (1) US20130101670A1 (es)
EP (1) EP2591781B1 (es)
JP (1) JP5000017B2 (es)
KR (1) KR20130113348A (es)
CN (1) CN102958522B (es)
AR (1) AR082139A1 (es)
AU (1) AU2011274851A1 (es)
BR (1) BR112013000298A2 (es)
CA (1) CA2804874C (es)
CL (1) CL2013000089A1 (es)
CO (1) CO6650363A2 (es)
EC (1) ECSP12012360A (es)
ES (1) ES2644064T3 (es)
MA (1) MA34460B1 (es)
MX (1) MX2013000282A (es)
NZ (1) NZ605562A (es)
PE (1) PE20131064A1 (es)
RU (1) RU2013105456A (es)
TN (1) TN2012000623A1 (es)
TW (1) TW201217001A (es)
UY (1) UY33499A (es)
WO (1) WO2012005365A1 (es)
ZA (1) ZA201300106B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112632C2 (uk) 2010-06-16 2016-10-10 Такеда Фармасьютикалз Ю.Ес.Ей., Інк. Дозована форма з модифікованим вивільненням фебуксостату (варіанти)
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
CN106267220B (zh) * 2015-05-14 2019-06-28 北京科信必成医药科技发展有限公司 愈创甘油醚氢溴酸右美沙芬无水吞服掩味制剂
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
JP4300652B2 (ja) 1998-09-21 2009-07-22 大正製薬株式会社 経口用固形製剤
JP3389205B2 (ja) 1999-06-29 2003-03-24 武田薬品工業株式会社 口腔内速崩壊錠
RU2311906C2 (ru) * 2001-11-21 2007-12-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Композиция препарата замедленного высвобождения для высвобождения ингибитора секреции кислоты в желудке и способ ее получения
JP2005023058A (ja) 2003-06-10 2005-01-27 Lion Corp 咀嚼型医薬製剤用薬物粒子及びその製造方法、並びに薬物粒子を含有する咀嚼型医薬固形製剤及びその製造方法
JP5062872B2 (ja) 2003-08-13 2012-10-31 東和薬品株式会社 不快な味を低減した口腔内崩壊錠剤
EP1915988A4 (en) * 2005-08-18 2012-07-25 Teijin Pharma Ltd COMPRESSOR COMPRISING MULTIPLE SEGMENTS CONTAINING MEDICAMENTS
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
JP5123517B2 (ja) * 2005-11-14 2013-01-23 帝人ファーマ株式会社 アンブロキソール口腔内速崩性錠剤
JP2008050324A (ja) * 2006-08-28 2008-03-06 Ohara Yakuhin Kogyo Kk 苦味遮蔽組成物。
JP5097488B2 (ja) 2006-09-13 2012-12-12 京都薬品工業株式会社 苦味マスキング
UA112632C2 (uk) * 2010-06-16 2016-10-10 Такеда Фармасьютикалз Ю.Ес.Ей., Інк. Дозована форма з модифікованим вивільненням фебуксостату (варіанти)

Also Published As

Publication number Publication date
EP2591781B1 (en) 2017-09-27
TN2012000623A1 (en) 2014-04-01
US20130101670A1 (en) 2013-04-25
JPWO2012005365A1 (ja) 2013-09-05
CA2804874A1 (en) 2012-01-12
RU2013105456A (ru) 2014-08-20
AU2011274851A1 (en) 2013-01-31
KR20130113348A (ko) 2013-10-15
AR082139A1 (es) 2012-11-14
CN102958522B (zh) 2015-12-16
EP2591781A4 (en) 2014-12-03
MA34460B1 (fr) 2013-08-01
CL2013000089A1 (es) 2013-03-08
MX2013000282A (es) 2013-02-11
UY33499A (es) 2012-01-31
CN102958522A (zh) 2013-03-06
EP2591781A1 (en) 2013-05-15
JP5000017B2 (ja) 2012-08-15
ZA201300106B (en) 2013-09-25
BR112013000298A2 (pt) 2016-05-31
ES2644064T3 (es) 2017-11-27
WO2012005365A1 (ja) 2012-01-12
ECSP12012360A (es) 2013-02-28
CA2804874C (en) 2019-07-23
PE20131064A1 (es) 2013-09-23
NZ605562A (en) 2013-11-29
TW201217001A (en) 2012-05-01

Similar Documents

Publication Publication Date Title
WO2012034079A3 (en) Macrolide dosage forms
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
CO6650363A2 (es) Preparación recubierta con partículas finas
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
WO2014172376A3 (en) Markers of tumor cell response to anti-cancer therapy
CO6620043A2 (es) Procedimiento de preparación de composiciones famacéuticas destinadas a la administración por vía oral que comprende uno o varios principios activos y las composiciones que las comprenden
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
CO6450625A2 (es) Sistema intrauterino para uso en tratamiento médico
BRPI0820308B8 (pt) composição farmacêutica compreendendo oxi-hidróxido de ferro em alta carga, seus usos e seus processos de preparação, e comprimido
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
WO2009063222A3 (en) Solid compositions
NZ619857A (en) A fast dissolving pharmaceutical composition
WO2014194435A3 (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component.
BR112012004967A2 (pt) forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
WO2014106116A8 (en) Therapeutic compositions comprising antibodies
MX2015017202A (es) Formulacion de liberacion modificada.
TR201010683A1 (tr) Vildagliptin formülasyonları.
EP2575842A4 (en) COMPOSITION COMPRISING THE EXTRACT OF PHYSALIS ALKEKENGI VAR. FRANCHETI HORT AS AN ACTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES
CL2014002896A1 (es) Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion.
WO2014130313A3 (en) Methods and compositions relating to the treatment of cancer
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
BR112015028302A2 (pt) formulação de pastilha de nicotina
JP2013100268A5 (es)